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The role of oxygen tension level is a well-known phenomenon that has been studied in oncology and
radiotherapy since about 60 years. Oxygen tension may inhibit or stimulate propagation of viruses
in vitro as well as in vivo. In turn modulating oxygen metabolism may constitute a novel approach to treat
viral infections as an adjuvant therapy. The major transcription factor which regulates oxygen tension
level is hypoxia-inducible factor-1 alpha (HIF-1α). Down-regulating the expression of HIF-1α is a possible
method in the treatment of chronic viral infection such as human immunodeﬁciency virus infection,
chronic hepatitis B and C viral infections and Kaposi sarcoma in addition to classic chemotherapy. The
aim of this review is to supply an updating concerning the inﬂuence of oxygen tension level in human
viral infections and to evoke possible new therapeutic strategies regarding this environmental condition.
& 2013 Elsevier Inc. All rights reserved.Introduction
As soon as 1936 Magill and Francis (1936) found that in
conditions of reduced oxygenation inﬂuenza virus does not pro-
pagate in vitro. In 1952 Kalter and Tepperman (1952) reported that
hypoxia down-regulates inﬂuenza replication in mice. But on the
other hand, Polonis et al. (1991) published an article in 1991
reporting that anaerobic conditions induce HIV expression in
infected T cell lines. Likewise Ebbesen et al. (1991) suggested that
the replication of Sendai virus, a murine parainﬂuenza virus
responsible for respiratory disease, was enhanced when infected
rhabdomyosarcoma cells were incubated at low oxygen pressure
(3% O2). In tissues, in vivo oxygen tension is low in regard to
ambient air (21%), ranging between 1% in the bone marrow and
14% in the lung (Ebbesen and Zachar, 1998), implicating that thisll rights reserved.
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orinet).relative physiological chronic hypoxia may inﬂuence the tropism
and expression of human viruses. Modulating the expression of
the major transcription factor implicated in the regulation of
oxygen tension level, i.e. hypoxia-inducible factor-1α (HIF-1α)
(Semenza and Wang, 1992), seems an interesting approach as a
complement to traditional viral chemotherapy, notably to ﬁght the
inescapable emergence of mutant resistant viral strains, a frequent
cause of treatment failure.Overview of oxygen sensors
Hypoxia-inducible factor (HIF) is the main transcription factor
that governs the alterations in gene expression that allow organ-
isms to adapt to hypoxia. HIF is expressed by all metazoan species
analyzed to date (Kaelin and Ratcliffe, 2008; Loenarz et al., 2011;
Semenza, 2012). HIF is a heterodimeric DNA-binding protein
composed of an O2-regulated α-subunit (HIF-1α) and a constitu-
tively expressed β-subunit (HIF-1β). Three HIF-α isoforms have
been found (HIF-1α, -2α and -3α). HIF-1α is thought to be the
primary mediator of hypoxia-induced gene expression. In nor-
moxic conditions, HIF-1α has a o5 min half-life because of
ubiquitination by an ubiquitin-ligase complex containing the von
Hippel–Lindau (pVHL) protein, and subsequent rapid degradation
by the proteasome. pVHL binding requires hydroxylation of pro-
line residues on HIF-1α by prolyl-hydroxylase domain proteins
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dioxygenase family (Ivan et al., 2001; Jaakkola et al., 2001; Hirota
and Semenza, 2005). In hypoxic conditions, pVHL is no longer able
to bind HIF-1α, resulting in HIF stabilization, increase in its
concentration, nuclear translocation and thus induction of tran-
scription of the HIF-1α target genes (Berra et al., 2006; Maxwell
et al., 1999).
HIF-1α activity is also regulated by O2-dependent transactiva-
tion: HIF-1α contains two transactivation domains (TAD) that bind
coactivators like CBP p300; transactivation by the coactivator
protein CBP p300 is prevented by hydroxylation of an asparagine
residue in TAD-C by the asparaginyl hydroxylase FIH-1 (factor
inhibiting HIF-1) (Hewitson et al., 2002; Lando et al., 2002). Both
stabilization and transactivation of HIF-1 induce the transcription
of over 200 genes, including those involved in angiogenesis,
erythropoiesis and anaerobic glycolysis The canonical DNA
sequence (HRE: Hypoxia responsible element) recognized by the
heterodimer HIF-1α/HIF-1β transcription factor is 5′RCGTG3′
where R is a purine (Semenza and Wang, 1992).
Recently, substantial evidence has indicated that others addi-
tional O2-sensitive signalling pathways are involved in the
response to hypoxia: signalling through the mammalian targets
of mTOR and through activation of the unfolded protein response
(UPR) (Wouters and Koritzinsky, 2008; Calfon et al., 2002). Low
oxygen tension enhances Hepatitis C virus (HCV) replication in an
HIF-1 alpha independent manner (Vassilaki et al, 2013). It was also
suggested that the STAT5 pathway is involved during hypoxia to
induce the enhancement of parvovirus B19 viral expression in
erythroid cells (Pillet et al., 2004; Chen et al., 2011). So, it is
probable that, in addition to the canonical pathway involved in
response to hypoxia, i.e. HIF-1α/VHL/PHD, other pathways exist
and they may play a role in activating or down-regulating cellular
and viral genes in hypoxic conditions (Majmundar et al., 2010).
In addition to this hypoxia – dependent stabilization system, a
range of other post – translational modiﬁcations and signalling
pathways, such as the PI3K/Akt and p42/p44 MAPkinases path-
ways, also affect HIF-1α synthesis, stability and activity (Bardos
and Ashcroft, 2005; Richard et al., 1999).Viruses as modulators of oxygen sensing
If classical interaction of HIF with the target site is observed in
hypoxia, it is now admitted that even in normoxia some factors are
able to stabilize HIF-1α (Quintero et al., 2006). Viral proteins may
induce PHD degradation. In addition, nitric oxide (NO) and
reactive oxygen species (ROS) can lead to HIF-1α stabilization
(Fig. 1A).Induction of PHD degradation
While PHDs are down-regulated, HIF-1α is stabilized in nor-
moxic conditions. This mechanism has been observed in vitro in
nasopharyngeal cells infected by the Epstein–Barr virus (EBV).
More precisely, the Latent Membrane viral Protein-1 (LMP-1) up-
regulates the level of E3 ubiquitin ligase which subsequently
induces the degradation of PHD-1 and -3 by the proteasome
(Kondo et al., 2006). It is necessary to be cautious since Benders
and colleagues, by examining 18 EBV positive nasopharyngeal
carcinoma tissue specimens, did not observe any correlation
between LMP-1 and HIF-1α expressions (Benders et al., 2009).
Nevertheless, it has more recently been reported that Epstein–Barr
nuclear antigens (EBNA), EBNA-5 and EBNA-3, bind to PHD 1 and 2,
respectively, thus inhibiting HIF-1α hydroxylation and degradation
(Darekar et al., 2012).Role of NO and ROS produced during viral infection
Respiratory syncytial virus (RSV) is the major cause of serious
lower respiratory disease in infancy and early childhood. RSV is
characterized by a particularly prominent inﬂammation of the
pulmonary mucosa in both natural and experimental infections.
In a mouse model of RSV infection, HIF-1α was stabilized in vivo
during murine RSV pneumonia, and in vitro in RSV-infected cell
cultures. The addition of an NO inhibitor blocked RSV-mediated
HIF-1α expression (Haeberle et al., 2008; Kilani et al., 2004).
ROS are produced during many viral infections and are the
stigma of chronic viral infections such as Human Immunodeﬁciency
Virus (HIV) infection. Two articles described an up-regulation of HIV
gene expression by HIF-1α in normoxic conditions. In the ﬁrst work,
the viral protein vpr induces ROS which contribute to HIF-1α
expression that, in turn, stimulates HIV-1 gene transcription by
forming an heterodimer with vpr (Deshmane et al., 2009, 2011).
Interestingly, this heterodimer binds a GC-rich region of the Long
Terminal Repeat (LTR) and not the canonic consensus site 5′RCGTG3′
recognized by the complex HIF-1α/HIF-1β. In an HIV transgenic rat
model, the production of ROS by HIV gp120 and tat induces the
synthesis of platelet derived growth factor (PDGF) via HIF-1α
stabilization and leads to pulmonary vascular remodelling
(Mermis et al., 2011). Nevertheless, only a fraction of HIV-infected
individuals (0.5%) develops a pulmonary hypertension suggesting
that the aetiology of this clinical situation is more complicated than
suggested.
Both microarray and proteomic studies have demonstrated
increased expression of oxidative stress response genes in HCV-
associated ﬁbrosis and cirrhosis. Oxidative stress, which stabilizes
HIF-α, has been recognized as a major procarcinogenic cofactor in
chronic HCV and hepatitis B virus (HBV) infections, especially by
inducing angiogenesis during hepatocarcinogenesis (Fung et al.,
2009; Moon et al., 2004).
Activation of intracellular kinases
The activation of HIF-1α by cellular kinases can be done by
inducing either RNA transcription or protein translation, or via
post-translational phenomena. Several viral proteins could inter-
fere with these kinases leading to an increase of HIF-1α activity.
At transcriptional level the human cytomegalovirus infection
resulted in an increase of HIF-1α-speciﬁc RNA; this phenomenon
was observed with irradiated viruses indicating that components
of the initial infecting virion are responsible, but it was not clear
whether Akt phosphorylation was vital for this induction
(McFarlane et al., 2011). It has also been shown in dermal human
endothelial cells that latent HHV-8 infection activates the tran-
scription of HIF-1α via Src kinase in normoxia (Carroll et al., 2006).
At translational level, the LMP1 protein of EBV increases HIF-1α
activity through induction of its protein expression, which is
controlled by the p42/p44 MAPK activity (Wakisaka et al., 2004).
At post translational level the protein encoded by the ORF3 of
Hepatitis E virus (HEV)stabilizes HIF-1α and also binds to MAPK
phosphatase that activates CBPp300 phosphorylation and conse-
quently the transcriptional activity of HIF-1α (Moin et al., 2009;
Kar-Roy et al., 2004). The HBx protein stabilizes HIF-1α via the
p42/p44MAPK pathway; it also induces the deacetylation of
the oxygen-dependent degradation domain of HIF-1α, leading to
the dissociation of PHD and pVHL from HIF-1α (Yoo et al., 2008, 2003).
For HCV, MEK and PI3-kinase inhibitors abolished HIF-1 α stabilization
induced by the viral non-structural proteins from NS3 to NS5B
(Nasimuzzaman et al., 2007). Several human papillomavirus (HPV)
types cause an enhancement of HIF-1α expression in hypoxia, an effect
that is mediated by increasing the stability of the HIF-1α protein; this
effect does not involve the PI3K/mTOR pathway as suggested by the
Fig. 1. (A) In normoxia, HIF-1α is degraded by the proteasome after prolyl-hydroxylation by a PHD (in presence of Fe and O2) and interaction with pVHL protein. Few
amounts of HIF-1α reach the nucleus (dotted line). In the nucleus an asparagyl-hydroxylase inhibits the interactions between HIF-1α and CBP/p300. Nevertheless, some
viruses are able to stabilize HIF-1α in normoxia via MAP-kinase and PI3/AKT kinase pathways for HBV, HHV-8, HEV and via NO and ROS for RSV, HCV, HIV-1 and HBV.
In addition, in normoxia, stabilization of HIF-1α is observed with viruses which degrade PHD (i.e. EBV) or which interact negatively with pVHL protein (i.e. HHV-8 and HBV).
(B) In hypoxia, HIF-1α is stabilized (1) and enters the nucleus (2) where it associates with HIF-1β and CBP/300. This complex interacts with a Hypoxia Responsive Element
(HRE) on the target genes (3). HRE sites are present on the promoters of HHV-8 and JCV, stimulating their replication. A non-conventional HRE site, a GC-rich region in the
LTR of HIV-1, promotes viral replication. In this case, the vpr protein of HIV-1 forms a complex with HIF-1α.
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in HPV positive cell lines (Nakamura et al., 2009).
Finally, once HIF-1α is stabilized, vGPCR, the G protein-coupled
receptor encoded by Human Herpes Virus-8 (HHV-8), enhances
its transcriptional activity notably from the vascular endothelial
growth factor (VEGF) promoter (Sodhi et al., 2000) through the
p38 and MAPK signal transduction pathway.HHV-8, the agent of Kaposi sarcoma and oxygen tension
level: A paradigm?
HHV-8 is a gamma-herpes virus associated with Kaposi sarcoma,
primary effusion lymphoma (PEL) and multicentric Castelman's
disease. From a pathogenic point of view, Kaposi sarcoma, a tumorof endothelial origin, could be the consequence of three processes:
proliferation of spindle cells, inﬂammation and angiogenesis
(Ganem, 2010; Ye and Gao., 2011).
Most of the spindle cells, cells speciﬁc of an advanced tumor,
are actually latently infected, but a minority of these cells express
markers of lytic infection. HHV-8 has been demonstrated to
reprogram endothelial cells with expression of lymphangiogenic
molecules (Wang et al., 2004) In vitro, induction of vGPCR expres-
sion in endothelial cells leads to the potent up-regulation of VEGF
in a Rapamycin sensitive manner. The increase of VEGF production
by vGPCR was blocked by the expression of a speciﬁc siRNA of
HIF-1α (Jham et al., 2011).
In Kaposi sarcoma, as described for other herpes viruses, the
viral genome can be expressed via either latency or lytic programs,
a bimodal expression. Both programs are on display in Kaposi
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lytic replication cycle in vitro: this activation has been attributed to
activation of Kaposi's Sarcoma-Associated herpes virus ORF34-37
gene cluster via a functional HRE (Davis et al., 2001; Haque et al.,
2003). In addition, the Latency-Associated Nuclear Antigen (LANA)
not only enhances the transcription level of HIF-1α mRNA but also
interacts with it to induce the lytic cycle by activating the
promoter of ORF50/RTA, the main viral protein associated with
lytic replication (Cai et al., 2006). It is noteworthy that the RTA
promoter contains 7 HRE putative motifs, of which 3 respond to
HIF. Moreover, the unfolded protein response (UPR), via the X-box
protein 1 (XBP-1), induces the HHV-8 lytic cycle under hypoxic
conditions in PEL cell lines by activating the RTA lytic promoter
(Dalton-Grifﬁn and Kellam, 2009). In other words, in hypoxic
conditions, there is a positive feedback between HIF-1α and
HHV-8 expression (Veeranna et al., 2012) (Fig. 2). Such a mecha-
nism may be also involved in normoxia since LANA targets the
HIF-1α suppressor factor pVHL for inducing HIF-1α stabilisation;
this stabilisation in normoxia also results from the interaction of
HIF-1αwith the HHV-8 viral Interferon Regulatory Factor-3 (vIRF3)
(Cai et al., 2007; Shin et al., 2008). The viral interactions with the
HIF pathway must be more complex: in a recent work Haque and
Kousoulas (2013) demonstrated that the ORF34 protein, the
transcription of which is activated by HIF after binding on HRE
located in the promoter region (Haque et al., 2003), is also able to
induce HIF degradation via the proteasome-dependent pathway.
All these data were obtained in PEL cell lines which originate
from lymphoid B cells. The extrapolation of these results to Kaposi
sarcoma, which derive from vascular endothelial cells, might be
convincing since KHSV latent infection was found to synergize
with hypoxia in endothelial cell to induced increased levels of
HIF-1α, an effect caused at least in part by LANA (Carroll et al., 2006).HIF-1α, a restriction factor of viral replication?
In addition to its role in promoting tumour growth, HIF-1α has
also been implicated as modulator of immune responses. For
example, the loss of HIF-1α impairs polymorphonuclear cell ability
to kill bacteria (Peyssonnaux et al., 2005). In turn, cytokines such
as interleukin-1 β, tumour necrosis factor α and interferon α can
activate HIF-1α expression (Eltzschig and Carmeliet, 2011). Such
interactions can impact some viral infections. For example, theFig. 2. HHV-8 infection may lead to a latent (blue line) or lytic cycle (red line). The
Latency-Associated Nuclear Antigen, LANA, enhances the transcription of HIF-1α
mRNA and interacts with its product, the HIF-1α protein, to activate the ORF50/RTA
promoter inducing lytic replication. HIF-1 alpha is also stabilized by hypoxia
(orange line) and consequently activates the ORF34-37 gene cluster, leading to
viral lytic cycle.replication of vesicular stomatitis virus (VSV), a zoonotic single-
stranded RNA virus belonging to the Rhabdoviridae family and
responsible for ﬂu-like illness in humans, is inhibited by HIF-1α
(Hwang et al., 2006). The 786-O (pVHL−/−) renal carcinoma cells
(RCCs), which display constitutive HIF activity, are more resistant
to the cytolytic effect of VSV than are RCCs expressing the wild-
type pVHL and exhibiting a low HIF-1α activity in normoxia. This
result, observed at a low-multiplicity of infection, suggests that
HIF-1α may be a general mediator of the antiviral response to VSV.
Like other restriction factors such as the APOBEC (apolipopro-
tein B mRNA editing enzyme, catalytic polypeptide-like) family
that restrains retroviruses replication, HIF-1α might be seen as a
constituent of innate response in some viral infections. So, if these
results obtained with VSV are relevant for other viruses, inducers
of HIF-1α signalling in antiviral therapy will merit further inves-
tigation. However, the problem would be very complex since HIF-
1α also enhances viral replication in many cases, either directly or
by inducing viral or cellular proteins that activate virus expression.
For example, the ubiquitous glucose transporter (Glut-1) is up-
regulated in response to low O2 in several cell types and it has
been observed that HIV infection susceptibility of human thymo-
cyte and CD4 T cells is correlated with Glut-1 expression (Loisel-
Meyer et al., 2012). The use of HIF inducers must be therefore
evaluated for every case, depending on the virus concerned.
Are inhibitors of HIF-1α useful for the treatment of viral infections?
A translational approach
Some viral genes are up-regulated by hypoxia via HRE (Fig. 1B).
Several studies suggest that the use of HIF inhibitor, either by
direct inactivation or by kinase blockade, may be useful for the
treatment of life-threatening chronic infections. As an example,
Erlotinib, an inhibitor of HIF-1α and of EGFR has been approved for
the treatment of non-small cell lung cancer; it may be useful for
the treatment of HCV-induced tumors because it has been demon-
strated to inhibit HCV entry in vitro, Lupberger et al. (2011).
Moreover, as the HBx protein of HBV increases the multidrug
resistance 1 transporter activity (MDR-1) via HIF-1α (Han et al.,
2007), inhibitors of HIF-1α might be useful, in combination with
Sorafenib, a multikinase inhibitor, for the treatment of patients
diagnosed at advanced stage of HBV-induced HepatoCellular
Carcinoma and for which conventional therapies are no more
successful (Forner et al., 2012). Another chronic infection, pro-
gressive multifocal leukoencephalopathy (PML) induced by the
John Cunningham virus (JCV) is an incurable disease: it has been
shown in vitro that HIF-1α can bind and activate the viral
promoter, suggesting that JCV could be a suitable target for an
inhibitor of HIF-1α (Piña-Oviedo and Del Valle, 2009). And as
suggested in a previous paragraph, use of HIF inhibitor may be
useful for the treatment of HHV-8 Kaposi sarcoma.
New insight of tumour treatment by using oncolytic viruses
There is ample evidence that solid tumours frequently encoun-
ter hypoxic stress and exhibit high levels of HIF-1α accumulation.
Studies on the ability of some viruses to be oncolytic in vitro and in
animal models have been conducted for many years (for reviews
see Rommelaere et al., 2010: Russell et al., 2012). This oncolytic
activity can be in part related to the interference with the HIF
pathway: as a proof, one of these oncolytic viruses, the human
Reovirus, was able to induce degradation of HIF-1α independently
of the pVHL E3 ubiquitin ligase activity in vitro (Cho et al., 2010).
However, for the moment, the use of these oncolytic viruses in
human disease is still uncertain and is evaluated in virotherapy
protocols. Some are under progress for the treatment of glioma
(Rommelaere et al., 2010). Another target would be the clear cell
F. Morinet et al. / Virology 444 (2013) 31–36 35subtype of Renal Cell Carcinoma (ccRCC), where the VHL protein is
deﬁcient and tumour cells express high levels of HIF-1α; virother-
apy would complement agents targeting VEGF and Rapamycin
mTOR kinase pathways, which have been demonstrated to
improve progression-free survival in both ﬁrst-line and second-
line settings (Coppin et al., 2011).Conclusion
Oxygen tension exerts signiﬁcant effects on virus replication
in vitro and probably also in vivo. The problem is more complex than
previously described since oxygen tension sometimes up-regulates
viral production whereas in other cases it down-regulates it (Pipiya
et al., 2005; Tomaskova et al., 2011), depending on the virus and the
system used to study virus replication in vitro. Nevertheless, HIF-1α
usually, seems to play a major role in modulating viral infection in
both normoxic and hypoxic conditions.
A growing number of drugs that inhibit HIF-1α have been
identiﬁed and validated as anticancer agents (Semenza, 2010).
Notably, cardiac glycosides like digoxin inhibit HIF-1 alpha in vitro
(Zhang et al., 2008) and are going to be used in association with
conventional chemotherapy in ErbB2 breast cancer (ClinicalTrials.
gov-key words: Digoxin and Cancer). Lessons learned in oncology
may inform new strategies in viral therapy. Effectively, the
challenge now is to use available HIF-1α inhibitors, in combination
with antiviral and/or chemotherapy agents in chronic viral dis-
eases such as HIV-induced immunodeﬁciency or viral hepatitis-
induced hepatocarcinogenesis in order to prevent the emergence
of resistance to conventional antiviral therapy. Moreover, the use
of digoxin, instead of anthracyclines which are cardiotoxic, in
combination with Bevacizumab, an antiangiogenic drug, will merit
further investigation for the treatment of Kaposi sarcoma (Uldrick
et al., 2012).
Close collaboration between fundamental scientists, clinical
oncologists and virologists is required to design, evaluate and
reﬁne strategies for translating research knowledge into safe and
effective antiviral therapies.Contributors
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